<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet type="text/xsl" href="https://www.peertechzpublications.org/assets/xsl/oaitohtml.xsl"?>
<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
										<responseDate>2026-06-03T17:02:09Z</responseDate>
										<request verb="GetRecord" metadataPrefix="oai_dc" identifier="oai:www.peertechzpublications.org:10.17352/2455-2283.000034">https://www.peertechzpublications.org/oai-pmh</request><GetRecord><record>
								<header>
									<identifier>oai:www.peertechzpublications.org:10.17352/2455-2283.000034</identifier>
									<datestamp>2017-05-18</datestamp>
									<setSpec>PTZ.ACG:VOL3</setSpec>
								</header>
								<metadata>
									<oai_dc:dc xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
										<dc:title>
										Influence of Long-Term Use of Proton Pump Inhibitors on Esophageal and Gastrointestinal Precancerous Lesions or Carcinoma
										</dc:title><dc:creator>Baoge QU</dc:creator><dc:creator> QU Hao</dc:creator><dc:description>&lt;p&gt;Patients with GERD and Barrett’s oesophagus should be encouraged to continue long term use of PPI therapy as a preventive measures for oesophageal adenocarcinoma. However, the conclusions, whether long-term use of PPI may casuse FGPs and gastric carcinoma development, remain inconsistent. Now, individual reports showed that long-term treatment with PPI might cause gastric neuroendocrine tumors (g-NETs) and the development of ECL cell carcinoids.Presently enormous study’s conclusion supported that long-term use of PPI does not increase in risk of colorectal cancer. Hence, clinical physicians must weigh potential risks of long-term use of PPI against gastrointestinal precancerous lesions or carcinoma.&lt;/p&gt;</dc:description>
										<dc:publisher>Archives of Clinical Gastroenterology - Peertechz Publications</dc:publisher>
										<dc:date>2017-05-18</dc:date>
										<dc:type>Review Article</dc:type>
										<dc:identifier>https://doi.org/10.17352/2455-2283.000034</dc:identifier>
										<dc:language>en</dc:language>
										<dc:rights>Copyright © Baoge QU et al.</dc:rights>
									</oai_dc:dc>
								</metadata>
							</record></GetRecord>
						</OAI-PMH>
